Airain Ltd’s Myriad Genetics MYGN Stock Holding History

Airain Ltd’s Portfolio MYGN Stock Details MYGN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2017 Q2	$1.1M	Buy	+42,460	New	+$901K	0.05%	389
2016 Q4	–	Sell	-57,986	Closed	-$1.19M	–	790
2016 Q3	$1.19M	Sell	57,986 -44,604	-43%	-$1.13M	0.07%	304
2016 Q2	$3.14M	Buy	102,590 +65,105	+174%	+$2.26M	0.18%	161
2016 Q1	$1.4M	Buy	+37,485	New	+$1.41M	0.1%	231
2015 Q4	–	Sell	-44,970	Closed	-$1.69M	–	978
2015 Q3	$1.69M	Buy	44,970 +16,417	+57%	+$583K	0.1%	256
2015 Q2	$971K	Sell	28,553 -17,992	-39%	-$612K	0.05%	366
2015 Q1	$1.65M	Sell	46,545 -9,284	-17%	-$332K	0.1%	228
2014 Q4	$1.9M	Sell	55,829 -1,093	-2%	-$38.8K	0.16%	166
2014 Q3	$2.19M	Buy	+56,922	New	+$2.12M	0.15%	191
2014 Q2	–	Sell	-16,000	Closed	-$547K	–	869
2014 Q1	$547K	Buy	+16,000	New	+$496K	0.1%	334
2013 Q4	–	Sell	-131,925	Closed	-$3.1M	–	664
2013 Q3	$3.1M	Buy	131,925 +88,796	+206%	+$2.52M	0.58%	34
2013 Q2	$1.16M	Buy	+43,129	New	+$1.25M	0.17%	144

Other funds holding MYGN

Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return

CCM

Consonance Capital Management New York $7.28M AUM 43.59% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

FCM

Frontier Capital Management Boston, Massachusetts $9.73B AUM 55.65% 1-Year Est. Return

CCM

Camber Capital Management Boston, Massachusetts $1.07B AUM 8.19% 1-Year Est. Return

Thrivent Financial for Lutherans Minneapolis, Minnesota $52.5B AUM 27.12% 1-Year Est. Return

Airain Ltd's MYGN Position: Q2 2017 in Review

Airain Ltd opened a new position in Myriad Genetics (MYGN) in Q2 2017: 42,460 shares worth $1.1M. The stake represents 0.05% of the portfolio and ranks #389 among its holdings. This is a return to the name: Airain Ltd previously reported a position in MYGN as recently as Q3 2016.

Airain Ltd first reported a position in MYGN in Q2 2013 and has held it in 12 quarters since. The position peaked at $3.14M in Q2 2016. 239 funds tracked by Wall St. Rank hold MYGN as of Q2 2017.

Airain Ltd held 42,460 shares of Myriad Genetics worth $1.1M as of Q2 2017.
Myriad Genetics was a new Airain Ltd position in Q2 2017.
Myriad Genetics made up 0.05% of Airain Ltd's portfolio in Q2 2017, its #389 holding.
Airain Ltd first reported a position in Myriad Genetics in Q2 2013 and has held it in 12 quarters since.
Airain Ltd's Myriad Genetics position peaked at $3.14M in Q2 2016.
239 funds tracked by Wall St. Rank held Myriad Genetics as of Q2 2017.

Based on Airain Ltd's 13F filing for Q2 2017, filed 8 Aug 2017.